Story perspectives

Quantum AI Predicts Neuroblastoma Better Than MYCN Biomarker

6/23/2026

Summary

Alter's Team Predicts

Orly Alter’s Utah team created a quantum AI method that uses spectral decompositions based on entanglement and superposition.
It integrates tumor and blood DNA and tumor RNA from 20-100 patients, avoiding the 33 trillion needed.
Testing on neuroblastoma data identified predictors that outperformed the MYCN biomarker.
The predictors, validated for glioblastoma outcomes using CRISPR-Cas9, were reported June 22 in Applied Physics Letters (APL) Quantum with NIH and NSF funding.

Summary

Prism AI Licenses

Prism AI Therapeutics, a University of Utah spinoff, is licensing its quantum multitensor platform to pharmaceutical firms, with funding from NIH, NSF and philanthropic foundations.
By linking predictions to explicit molecular pathways, the algorithm may simplify regulatory review compared with typical black-box AI models.
Researchers blended biomedical engineering, computational science, quantum physics and clinical oncology, creating a cross-disciplinary model applicable to noisy high-dimensional data in fields such as sustainable energy.

1 of 2

Alter's Team Predicts

Orly Alter’s Utah team created a quantum AI method that uses spectral decompositions based on entanglement and superposition.
It integrates tumor and blood DNA and tumor RNA from 20-100 patients, avoiding the 33 trillion needed.
Testing on neuroblastoma data identified predictors that outperformed the MYCN biomarker.
The predictors, validated for glioblastoma outcomes using CRISPR-Cas9, were reported June 22 in Applied Physics Letters (APL) Quantum with NIH and NSF funding.

1 / 2